Overview

A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2028-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and tolerability and overall survival (OS) of E-EDV-D682/GC in combination with gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone in participants with metastatic pancreatic ductal adenocarcinoma (PDAC) who have progressed on therapy.

Phase:

PHASE1

Details

Lead Sponsor:

Engeneic Pty Limited

Collaborator:

Herbert Irving Comprehensive Cancer Center

Treatments:

Gemcitabine
Taxes